Jeffrey Chodakewitz has been appointed a member of the board of directors of Freeline Therapeutics Ltd which is developing gene therapies for haemophilia and other chronic diseases. Dr Chodakewitz has more than 30 years of executive experience in the biopharmaceutical industry, most recently as chief medical officer at Vertex Pharmaceuticals Inc where he oversaw development of the company’s cystic fibrosis medicines. Before that, he was an executive at Merck & Co Inc. He holds an MD from the Yale University School of Medicine, US.
Freeline announced the appointment on 5 November 2019.
